Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study

Southern University of Science and Technology

Status: Unknown

Conditions: Lipid Metabolism; Cardiovascular Diseases

Treatments: Drug: PCSK9 inhibitor

Study type: Interventional

Funder types: Other

Identifiers

NCT04730648

Among-Us study

Details and patient eligibility

About

Acute coronary syndrome (ACS) is a lethal disease, reduced low-density lipoprotein (LDL) cholesterol due to inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) reduces cardiovascular events and improve cardiovascular prognosis. we assuming that PCSK9 inhibitor could bring metabolic change in serum, in order to investigate the metabolic modification, we conduct this clinical trial.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• New diagnosis ACS patient by serum biomarker and coronary arteriography.

Exclusion criteria

• Severe renal dysfunction acute or chronic bacterial and viral infections sleep apnea cancer

Trial design

Primary purpose: Screening

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

pcsk9 inhibitor group

Experimental group

Description:

patients with severe coronary stenosis diagnosed ACS. The baseline blood and urine would be collected, thereafter, the PCSK9 inhibitor would be injected. 64-72 hours after, the blood and urine sample collection would be performed.

Treatment:

Drug: PCSK9 inhibitor

control group

No Intervention group

Description:

Patients with comparable age, sex ratio, and BMI, but coronary arteries are relatively normal evaluated by coronary angiography. their blood and urine would be collected as the control group.